The H5N1 strain of avian influenza remains an ever-present threat due to its persistent circulation among avian populations and sporadic spillover events into humans, manifesting a pandemic risk that demands urgently scalable and efficacious vaccines. Traditional influenza vaccines, typically administered via intramuscular injections, have demonstrated efficacy primarily by stimulating systemic immune responses. While protective against symptomatic disease when vaccine strains are well-matched to circulating viruses, these vaccines do not robustly induce mucosal immunity—the frontline defense at the respiratory tract, through which influenza viruses initiate infection and transmission.

Recognizing these limitations, the University of Maryland research team tested an intranasal vaccine formulation incorporating BlueWillow’s proprietary NanoVax® W_805EC adjuvant. This adjuvant is designed to enhance antigen presentation and potentiate both mucosal and systemic immune responses. The trial enrolled 40 healthy adult participants who were randomized to receive varying doses of this recombinant H5 vaccine, with control groups receiving either placebo or high-dose vaccine without the adjuvant. Six months post-administration, all participants received an intramuscular H5 booster dose, allowing researchers to evaluate priming effects conferred by the nasal vaccine.

Safety data from the trial were very encouraging: the intranasal NanoVax H5 vaccine was well tolerated with no serious adverse events reported. Critically, only subjects receiving the adjuvanted nasal vaccine demonstrated pronounced immune priming, evident as a robust immunological response to the subsequent injected booster. This priming effect was characterized by elevated titers of mucosal IgA and systemic IgG antibodies, increased frequencies of memory B and T cells, and augmented antibody-dependent cellular cytotoxicity (ADCC)—all of which are pivotal for comprehensive antiviral defense.

Importantly, this intranasal approach succeeded in eliciting cross-protective immunity against diverse clades of H5N1 viruses. This breadth of protection is significant, given the antigenic drift and evolution common to influenza viruses that often undermine vaccine efficacy. The NanoVax-adjuvanted vaccine’s ability to prime the immune system to recognize variant strains suggests a promising strategy to outpace viral mutation and provide durable pandemic preparedness.

The underlying immunological mechanisms seem to hinge on the capacity of mucosal immunization to activate specialized immune cells residing in the respiratory tract, which systemic injections alone fail to engage effectively. Mucosal IgA antibodies can neutralize pathogens at the portal of entry, while cellular immune responses facilitate rapid clearance of infected cells. The adjuvant’s role in amplifying these responses likely involves stimulation of innate immune pathways that enhance antigen uptake and presentation, thereby fostering the development of adaptive immunity.

Co-lead authors Meagan E. Deming, MD, PhD, and Franklin R. Toapanta, MD, PhD, emphasize the transformative potential of this vaccine platform—not only does it offer a needle-free, user-friendly method of administration increasing vaccine acceptance, but it also promises to stretch vaccine supplies by enabling dose sparing, an advantage during outbreak scenarios when rapid mass vaccination is essential.

The research also highlights that intranasal vaccines could significantly reduce viral transmission by establishing immunity where infection and viral shedding predominantly occur. In contrast to conventional intramuscular vaccines primarily effective at reducing severe disease, mucosal vaccination could curtail community spread by rapidly neutralizing the virus in the upper respiratory tract.

This trial’s success marks a significant milestone in influenza vaccine development by revealing tangible clinical proof of concept for mucosal vaccines against H5N1 influenza—an achievement long pursued but rarely attained in prior studies. The findings advocate for expanded clinical trials to optimize vaccine dosing, extend immunogenicity duration, and explore protection efficacy in diverse populations, including those with heightened vulnerability.

Funded by the National Institute of Allergy and Infectious Diseases, this research aligns strategically with global public health goals to curb influenza pandemics. As Mark T. Gladwin, MD, Dean of the University of Maryland School of Medicine, notes, the study accentuates the necessity of probing mucosal immune biomarkers and novel correlates of protection, both critical for accelerating the regulatory approval and deployment of next-generation intranasal vaccines.

The University of Maryland School of Medicine reinforces its reputation at the forefront of biomedical innovation, leveraging interdisciplinary expertise and cutting-edge biotechnologies to address urgent infectious disease challenges. Their Center for Vaccine Development and Global Health continues a storied legacy, having contributed significantly to vaccine advances against cholera, typhoid, malaria, and recently COVID-19, now breaking new ground in respiratory pathogen prevention.

As influenza viruses relentlessly evolve, capable of triggering potential pandemics, this novel intranasal adjuvanted H5N1 vaccine exemplifies a promising advancement. It integrates immunological insight with innovative delivery to yield a scalable, practical solution that could revolutionize influenza prevention globally — offering a beacon of hope against the relentless threat of avian influenza and enhancing pandemic preparedness.

Subject of Research: People
Article Title: An Intranasal Adjuvanted, Recombinant Influenza A/H5 Vaccine Primes Against Diverse H5N1 Clades: A Phase I Trial
News Publication Date: 6-Nov-2025
Web References: https://www.medschool.umaryland.edu/
References: DOI: 10.1038/s41467-025-64686-3
Keywords: Avian influenza, Vaccine development, Epidemics

CAR T cell therapy, a revolutionary form of personalized immunotherapy that was first developed by Dr. Carl June and his research team at Penn, has already transformed the treatment landscape for various blood cancers. However, despite its success, challenges persist as over half the lymphoma patients treated with currently approved CAR T products fail to maintain long-term remission. With only seven FDA-approved CAR T therapies to date, four targeting B-cell lymphomas specifically, the options for patients who relapse or develop resistance to these therapies remain limited and largely ineffective. Trying to re-treat patients with existing CAR T cells has demonstrated minimal benefits, highlighting the urgent need for novel strategies to overcome immune evasion and therapy resistance.

The recent clinical trial, led by Dr. Jakub Svoboda at Penn Medicine’s Abramson Cancer Center, represents a critical advancement in this field. The trial tested an innovative CAR T cell product known as huCART19-IL18, designed to enhance anti-tumor activity by incorporating an immunostimulatory cytokine, interleukin 18 (IL18), into the CAR T cell construct. This strategic modification creates an “armored” CAR T cell capable of not only targeting the CD19 antigen on lymphoma cells but also secreting IL18 to recruit and activate additional immune components. This multifaceted immune amplification bolsters CAR T cell persistence and potency in combating aggressive lymphoma.

Importantly, the addition of IL18 did not increase the risk of adverse effects commonly associated with CAR T cell therapies, such as cytokine release syndrome or neurotoxicity. These side effects remained manageable within existing clinical protocols, underscoring the safety of this cytokine-enhanced approach. The trial further suggested that the therapeutic efficacy of huCART19-IL18 might depend on the specific CAR T cell treatment a patient had previously received, hinting at critical interplay between therapy history and immune microenvironment that warrants deeper investigation.

Patients enrolled in this clinical trial had exhausted an average of seven prior therapeutic regimens, with all but one previously treated with an approved CAR T cell therapy. The persistence and progression of lymphoma after such extensive treatment underline the formidable challenge of immune suppression and T cell exhaustion, phenomena that blunt the effectiveness of cancer immunotherapies. By engineering CAR T cells to secrete IL18, the research team aimed to reinvigorate these defenses, enhancing the recruitment and activation of immune cells in the tumor microenvironment, thereby overcoming the hurdles that dampen anti-cancer immune responses.

Dr. Carl June, Richard W. Vague Professor in Immunotherapy, emphasized the significance of this achievement, noting the groundbreaking nature of the study as the first demonstration of cytokine-enhanced CAR T therapy in hematological malignancies. By dissecting post-treatment blood samples, the team provided compelling evidence that IL18 secretion not only improved CAR T cell expansion and persistence in vivo but also augmented the overall anti-tumor immune response. Such enhancements could be the key to extending CAR T cell therapy’s success beyond blood cancers into notoriously treatment-resistant solid tumors.

One of the technological breakthroughs enabling this advancement is the accelerated manufacturing process developed by Penn’s Center for Cellular Immunotherapies, which produces huCART19-IL18 cells in just three days, significantly shorter than the conventional nine to fourteen days required for commercial CAR T cell products. This reduction in production time is not only clinically advantageous—allowing patients with rapidly progressing cancers to initiate therapy sooner—but may also preserve the quality and potency of the T cells by limiting their ex vivo expansion. Prior studies have suggested this shortened culture period maintains a less differentiated T cell phenotype, potentially translating to superior therapeutic efficacy.

Ambitious plans are already underway to expand the clinical applications of this armored CAR T technology. Follow-up trials will include patients with acute lymphocytic leukemia (ALL) and chronic lymphocytic leukemia (CLL), diseases where CAR T therapies have demonstrated some success but still face significant obstacles. Additionally, a similar IL18-enhanced product is being tested in another trial targeting non-Hodgkin’s lymphoma, highlighting the versatility and broad potential of cytokine-armed CAR T cells. Collaborative efforts with Penn spinout companies aim to refine and scale up manufacturing processes, optimizing the creation and expansion of these formidable therapeutic agents.

Dr. Svoboda reflects on the collaborative environment at Penn that made this translational leap possible—an ecosystem where patient participation, scientific inquiry, and clinical expertise merge seamlessly. The comprehensive biopsies and cytokine analyses emerging from this trial provide invaluable insights into why CAR T therapies eventually fail in certain patients, equipping researchers with crucial data to refine strategies that prevent relapse. This knowledge feeds a cycle of continuous improvement, accelerating the development of next-generation cellular immunotherapies.

This breakthrough in CAR T therapy marks a paradigm shift not only for lymphoma patients but also for the future of cancer treatment. By harnessing the immune system’s inherent complexity and reinforcing it with engineered cytokine support, researchers have charted a path toward more durable, effective, and possibly curative options for patients with otherwise refractory malignancies. The implications extend even further, as cytokine-enhanced CAR T cells stand poised to tackle solid tumors—a frontier where previous cellular therapies have struggled due to immune evasion and physical tumor barriers.

In the broader context of immuno-oncology, this advancement underscores the power of sophisticated genetic engineering combined with biological insights into tumor immunology. Armed with IL18, CAR T cells represent a new class of multi-modal immunotherapeutics capable of orchestrating a systemic immune attack. This approach embodies the cutting edge of precision medicine where treatments are not only personalized but also dynamically augmented to meet the evolving challenges posed by cancer cells.

This landmark study, published in the prestigious New England Journal of Medicine, heralds a vital turning point in the fight against lymphoma and potentially other hematologic cancers. As the research community builds upon these findings, patients facing the bleak aftermath of treatment failure may soon access highly effective, durable therapies that were once unimaginable. The fusion of innovative scientific concepts, advanced manufacturing techniques, and clinical courage reflects the ongoing transformation in how cancer is understood and treated.

Subject of Research: CAR T cell therapy enhancement for refractory B-cell lymphomas utilizing cytokine (IL18) secretion to improve efficacy and durability.

Article Title: Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure

News Publication Date: 8-May-2025

Web References:

• Clinical trial: https://clinicaltrials.gov/study/NCT04684563
• NEJM publication: http://dx.doi.org/10.1056/NEJMoa2408771

References: Study published in the New England Journal of Medicine, Arkansas Comprehensive Cancer Center clinical trial data, Penn Medicine research disclosures.

Keywords: Chimeric antigen receptor therapy, Cancer immunotherapy, Lymphoma, B cell lymphoma, Cancer research

Thyroid cancers such as anaplastic thyroid cancer (ATC) and poorly differentiated thyroid cancer (PDTC) are characterized by their aggressive nature and poor prognosis, with conventional treatments offering limited survival benefits and an average patient lifespan often measured in months. AIC100’s targeted mechanism seeks to address the critical unmet need in these diseases by leveraging the immune system’s cytotoxic T lymphocytes, reprogrammed to recognize and eradicate ICAM-1 expressing tumor cells. This therapeutic approach not only signifies a novel strategy for thyroid cancers but also expands the potential horizons of CAR T cell technology.

The AIC100 construct represents a third-generation CAR T cell, incorporating enhancements intended to improve efficacy and persistence within the hostile tumor microenvironment of solid cancers. Specifically, AIC100’s CAR molecule binds the ICAM-1 protein, a transmembrane glycoprotein frequently overexpressed in ATC and PDTC cells, facilitating tumor infiltration and cytotoxic activity. Importantly, the CAR T cells co-express somatostatin receptor 2, allowing real-time in vivo tracking using positron emission tomography (PET) imaging, a sophisticated adaptation that enables clinicians to monitor distribution and treatment response non-invasively.

In this multicenter Phase I trial, 24 adult patients with newly diagnosed or relapsed/refractory ATC or PDTC were enrolled, many of whom had exhausted standard-of-care therapies with an average of two prior treatment regimens. The study employed a dose-escalation design exploring three initial dose levels of AIC100 administered after a lymphodepleting chemotherapy regimen, intended to enhance CAR T cell engraftment by reducing host regulatory immune cells. Of these patients, 15 received the investigational therapy, and evaluable data from dose levels two and three revealed encouraging clinical activity.

Specifically, among four ATC patients treated at the higher dose cohorts, the overall objective response rate reached 50%, with one achieving a complete response and another demonstrating a partial response. This level of tumor reduction and durable disease control, sustained up to seven months post-infusion, is unprecedented in this patient population. Moreover, in five PDTC patients, 60% experienced disease stabilization, suggesting both types of thyroid cancer may be amenable to this immunotherapeutic approach.

Safety signals from the trial were favorable, with no dose-limiting toxicities observed at the first three dose levels. Most adverse events comprised mild to moderate cytokine release syndrome (CRS), a common immune activation-related toxicity seen in CAR T therapies, which was manageable and transient. Notably, no cases of immune effector cell-associated neurotoxicity syndrome (ICANS), a frequent and serious complication in CAR T cell treatment, were reported. However, exploration of a fourth, escalated dose revealed the emergence of grade 3 pneumonitis in two patients, underscoring the necessity for careful dose optimization.

The safety profile combined with early efficacy led investigators to select dose level three as the recommended dose for future Phase II trials. These findings provide a compelling proof of concept for the application of CAR T cell therapy in solid tumors, an area historically fraught with challenges due to tumor heterogeneity, immune suppression within the tumor microenvironment, and physical barriers to T cell trafficking.

AIC100’s innovative design, including the somatostatin receptor PET-tracking feature, offers an important tool for understanding CAR T cell kinetics and persistence over time, which are critical parameters linked to long-term therapeutic success. This dual functionality may enable dynamic treatment adjustments and early identification of resistance or relapse, ultimately improving patient outcomes through precision immunotherapy.

Samer Srour, MB ChB, associate professor and principal investigator of the trial, emphasized the transformative potential these results hold. He noted that achieving complete and partial remissions in such an aggressive clinical setting is both a validation of the therapeutic strategy and an impetus for further development. The prospect of durable remissions could shift the current therapeutic landscape and significantly extend survival for patients afflicted with these lethal thyroid cancer subtypes.

This Phase I study was funded by AffyImmune Therapeutics, reflecting a productive academic-industry collaboration crucial for advancing cutting-edge immuno-oncology interventions. As the team prepares for larger-scale investigations, the oncology community eagerly anticipates more robust data on efficacy and long-term safety that could pave the way for regulatory approval and expanded clinical use.

In summary, the promising safety and efficacy profile of AIC100 in this early clinical evaluation signals a new frontier in the treatment of solid tumors, highlighting the potential for tailored CAR T cell therapies to overcome previous barriers and improve outcomes in hard-to-treat thyroid cancers. Further developments in this line of research could bring a much-needed paradigm shift, transforming fatal diagnoses into manageable chronic conditions or potentially curable diseases.

Subject of Research: CAR T cell therapy targeting ICAM-1 in aggressive thyroid cancers
Article Title: Novel CAR T Cell Therapy AIC100 Shows Promising Early Results in Aggressive Thyroid Cancers
News Publication Date: April 29, 2025
Web References:

• https://www.mdanderson.org/treatment-options/car-t-cell-therapy.html
• https://www.mdanderson.org/cancer-types/thyroid-cancer.html
• https://faculty.mdanderson.org/profiles/samer_srour.html
• https://www.abstractsonline.com/pp8/#!/20273/presentation/10430
• https://www.aacr.org/meeting/aacr-annual-meeting-2025/
• https://MDAnderson.org/AACR
  Image Credits: The University of Texas MD Anderson Cancer Center
  Keywords: Cancer treatments, Cell therapies, Thyroid cancer, Cancer patients, T cell responses, Clinical trials, T lymphocytes, Thyroid diseases, Gene targeting, Cellular proteins, Solid tumors, Target proteins, Cancer research, Cancer relapse, Neurological disorders, Tumor cells, Disease control